Functional, biophysical, and structural bases for antibacterial activity of tigecycline

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2156-2166

  Olson, Matthew W ^a,d   Ruzin, Alexey ^a,c   Feyfant, Eric ^b   Rush III, Thomas S ^b,e   O'Connell, John ^a   Bradford, Patricia A ^a  

^a WYETH RESEARCH   (United States)

^b PFIZER INC   (United States)

^c Johnson and Johnson Pharmaceutical Research and Development ^*  (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCYLCYCLINE DERIVATIVE; MINOCYCLINE; TETRACYCLINE; TIGECYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG MECHANISM; DRUG POTENCY; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RIBOSOME SUBUNIT; STRUCTURE ACTIVITY RELATION; THERMUS THERMOPHILUS; X RAY DIFFRACTION;

ANTI-BACTERIAL AGENTS; BINDING SITES; BINDING, COMPETITIVE; BIOPHYSICS; COMPUTER SIMULATION; HYDROGEN BONDING; KINETICS; MINOCYCLINE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BIOSYNTHESIS; RIBOSOMES; TETRACYCLINE; THERMUS THERMOPHILUS; X-RAY DIFFRACTION;

EID: 33744458965     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01499-05     Document Type: Article

References (31)

1. 2+ cleavage of 16S rRNA. J. Antimicrob. Chemother. 53:592-599.
2. Bergeron, J., M. Ammirati, D. Danley, L. James, M. Norcia, J. Retsema, C. A. Strick, W. G. Su, J. Sutcliffe, and L. Wondrack. 1996. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. 40:2226-2228.
3. Boucher, H. W., C. B. Wennersten, and G. M. Eliopoulos. 2000. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44:2225-2229.
4. Bouchillon, S. K., D. J. Hoban, B. M. Johnson, T. M. Stevens, M. J. Dowzicky, D. H. Wu, and P. A. Bradford. 2005. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn. Microbiol. Infect. Dis. 51:291-295.
5. Bradford, P. A. 2004. Tigecycline: a first in class glycylcycline. Clin. Microbiol. Newsl. 26:163-168.
6. Brodersen, D. E., W. M. Clemons, Jr., A. P. Carter, R. J. Morgan-Warren, B. T. Wimberly, and V. Ramakrishnan. 2000. The structural basis for the action of the antibiotics tetracycline, pactamycin, and hygromycin B on the 30S ribosomal subunit. Cell 103:1143-1154.
7. Chopra, I. 2002. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist. Updates 5:119-125.
8. Cull, M. G., and C. S. McHenry. 1995. Purification of Escherichia coli DNA polymerase III holoenzyme. Methods Enzymol. 262:22-35.
9. Dean, C. R., M. A. Visalli, S. J. Projan, P. E. Sum, and P. A. Bradford. 2003. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob. Agents Chemother. 47:972-978.
10. Epe, B., and P. Woolley. 1984. The binding of 6-demethylchlortetracycline to 70S, 50S and 30S ribosomal particles: a quantitative study by fluorescence anisotropy. EMBO J. 3:121-126.
11. Kiel, M. C., H. Aoki, and M. C. Ganoza. 1999. Identification of a ribosomal ATPase in Escherichia coli cells. Biochimie 81:1097-1108.
12. Labthavikul, P., P. J. Petersen, and P. A. Bradford. 2003. In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob. Agents Chemother. 47:3967-3969.
13. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
14. McAleese, F., P. Petersen, A. Ruzin, P. M. Dunman, E. Murphy, S. J. Projan, and P. A. Bradford. 2005. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob. Agents Chemother. 49:1865-1871.
15. McMartin, C., and R. S. Bohacek. 1997. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Des. 11:333-344.
16. McMurry, L. M., and S. B. Levy. 2000. Tetracycline resistance in gram-positive bacteria, p. 660-677. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-positive pathogens. ASM Press, Washington, D.C.
17. Moazed, D., S. Stern, and H. F. Noller. 1986. Rapid chemical probing of conformation in 16 S ribosomal RNA and 30 S ribosomal subunits using primer extension. J. Mol. Biol. 187:399-416.
18. Murphy, T. M., J. M. Deitz, P. J. Petersen, S. M. Mikels, and W. J. Weiss. 2000. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob. Agents Chemother. 44:3022-3027.
19. Petersen, P. J., and P. A. Bradford. 2005. Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent Oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob. Agents Chemother. 49:3910-3918.
20. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
21. Petersen, P. J., N. V. Jacobus, W. J. Weiss, P. E. Sum, and R. T. Testa. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
22. Pioletti, M., F. Schlunzen, J. Harms, R. Zarivach, M. Gluhmann, H. Avila, A. Bashan, H. Bartels, T. Auerbach, C. Jacobi, T. Hartsch, A. Yonath, and F. Franceschi. 2001. Crystal structures of complexes of the small ribosomal subunit with tetracycline, edeine and IF3. EMBO J. 20:1829-1839.
23. Rasmussen, B. A., Y. Gluzman, and F. P. Tally. 1994. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob. Agents Chemother. 38:1658-1660.
24. Rush, T. S., III, E. Manas, G. Tawa, and J. Alvarez. 2005. Solvation-based scoring for high throughput docking, p. 249-273. In J. Alvarez and B. Shoichet (ed.), Virtual screening in drug discovery. CRC Press, Boca Raton, Fla.
25. Ruzin, A., D. Keeney, and P. A. Bradford. 2005. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob. Agents Chemother. 49:791-793.
26. Ruzin, A., M. A. Visalli, D. Keeney, and P. A. Bradford. 2005. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 49:1017-1022.
27. Sum, P. E., V. J. Lee, R. T. Testa, J. J. Hlavka, G. A. Ellestad, J. D. Bloom, Y. Gluzman, and F. P. Tally. 1994. Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J. Med. Chem. 37:184-188.
28. Sum, P. E., and P. Petersen. 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9:1459-1462.
29. Tritton, T. R. 1977. Ribosome-tetracycline interactions. Biochemistry 16:4133-4138.
30. Visalli, M. A., E. Murphy, S. J. Projan, and P. A. Bradford. 2003. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob. Agents Chemother. 47:665-669.
31. Wang, J., P. Morin, W. Wang, and P. A. Kollman. 2001. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of T1BO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J. Am. Chem. Soc. 123:5221-5230.